Comparison of safety and efficacy between drug-coated balloon angioplasty and self-expanding stenting in symptomatic middle cerebral artery stenosis
10.3760/cma.j.cn115354-20240912-00564
- VernacularTitle:药物涂层球囊与自膨式支架治疗症状性大脑中动脉狭窄的安全性与有效性对比研究
- Author:
Tianming XU
1
;
Wenbo LIU
1
;
Tianxiao LI
1
;
Yanyan HE
1
;
Qianhao DING
1
;
Yingkun HE
1
Author Information
1. 河南省人民医院（郑州大学人民医院）脑血管病科 河南省脑血管病国际联合实验室 河南省脑血管介入创新工程技术研究中心，郑州 450003
- Publication Type:Journal Article
- Keywords:
Drug-coated balloon;
Self-expanding stent;
Middle cerebral artery;
Ischemic stroke
- From:
Chinese Journal of Neuromedicine
2025;24(1):23-28
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To compare the efficacy of drug-coated balloon (DCB) angioplasty and self-expanding stenting in symptomatic middle cerebral artery stenosis (MCAS).Methods:A retrospective study was performed. Patients with symptomatic MCAS admitted to Department of Cerebrovascular Diseases, Interventional Center, He'nan Provincial People's Hospital from January 2020 to December 2022 were chosen from their prospective study database. They were divided into a DCB group and a stent group based on approaches. Baseline data differences between the two groups were eliminated using 1: 1 propensity score matching (PSM). Then, the technical success rate, immediate restenosis rate, and 6-month restenosis rate, and clinical outcomes within 30 days and 1 year of procedure were compared between the two groups.Results:After PSM, 58 patients were included, with 29 in the stent group and 29 in the DCB group. Technical success rate was 93.1% (27/29) in the DCB group and 96.6% (28/29) in the stent group, without significant difference ( P>0.05). The immediate restenosis rate was 6.9% (2/29) in the DCB group and 3.4% (1/29) in the stent group, without significant difference ( P>0.05). In terms of safety, no stroke or death events were noted in the two groups within 30 days of procedure; ischemic stroke incidence in the offending vessel areas within 1 year of procedure in the DCB group and stent group was 3.7% (1/27) and 11.5% (3/26), without significant difference ( P>0.05); no hemorrhagic stroke or death were noted in the two groups within 1 year of procedure. In terms of efficacy, the modified Rankin scale score of the two groups was both 0 (0, 0) at 1 year of follow-up, without significant difference ( P>0.05); 46 patients in the DCB group and stent group had imaging followe-up for 6 months: the restenosis rate was 8.0% (2/25) and 23.8% (5/21), respectively, without significant difference ( P>0.05). Conclusion:DCB angioplasty is comparable in efficacy and safety with self-expanding stenting in symptomatic MCAS.
